Exclusive Summary

• Originator patents have expired, but high barriers in API synthesis and specialized packaging keep the global generic market in an oligopoly, offering distributors a high-margin, low-competition opportunity.
• Due to its ultra-low blood-gas partition coefficient, it is an essential general anesthetic for ERAS protocols, ensuring extremely rapid emergency for obese, elderly, and outpatient surgery patients.
• Backed by over 300 million major surgeries globally per year, this high-quality Chinese generic provides a robust solution to recurrent global shortages of inhalation anesthetics.
• The 240ml standard packaging is fully compatible with mainstream heated vaporizers, providing significant cost advantages over the originator (Suprane) that perfectly align with global DRG cost-containment policies.